These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 29404792)
21. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508 [TBL] [Abstract][Full Text] [Related]
22. Effect of intrathecal dexmedetomidine on spinal morphine analgesia in patients with refractory cancer pain. Liu HJ; Gao XZ; Liu XM; Xia M; Li WY; Jin Y J Palliat Med; 2014 Jul; 17(7):837-40. PubMed ID: 24702571 [TBL] [Abstract][Full Text] [Related]
23. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507 [TBL] [Abstract][Full Text] [Related]
24. Ziconotide: an update and review. Williams JA; Day M; Heavner JE Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786 [TBL] [Abstract][Full Text] [Related]
25. Intrathecal therapy for pain in cancer patients. Dupoiron D Curr Opin Support Palliat Care; 2019 Jun; 13(2):75-80. PubMed ID: 30896454 [TBL] [Abstract][Full Text] [Related]
26. [Recommendations for the management of chronic pain by intrathecal ziconotide]. Tronnier V; Hofacker W; Ilias W; Kleinmann B; Koulousakis A; Kress HG; Likar R; Lux EA; Müller-Schwefe G; Schütze G; Uberall M MMW Fortschr Med; 2010 Oct; 152 Suppl 3():106-9. PubMed ID: 21595155 [No Abstract] [Full Text] [Related]
27. Ziconotide: a clinical update and pharmacologic review. Pope JE; Deer TR Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340 [TBL] [Abstract][Full Text] [Related]
28. In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps. Dupoiron D; Richard H; Chabert-Desnot V; Devys C; Leynia P; Boisdron-Celle M Neuromodulation; 2014 Jul; 17(5):472-82; discussion 482. PubMed ID: 24512055 [TBL] [Abstract][Full Text] [Related]
29. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy. Prusik J; Argoff C; Peng S; Pilitsis JG Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135 [TBL] [Abstract][Full Text] [Related]
30. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287 [TBL] [Abstract][Full Text] [Related]
31. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Patel VB; Manchikanti L; Singh V; Schultz DM; Hayek SM; Smith HS Pain Physician; 2009; 12(2):345-60. PubMed ID: 19305484 [TBL] [Abstract][Full Text] [Related]
32. [Chronic intrathecal drug administration for the control of intractable pain]. Taira T Brain Nerve; 2008 May; 60(5):509-17. PubMed ID: 18516973 [TBL] [Abstract][Full Text] [Related]